VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Eli Lilly and Company vs Merck & Co., Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Eli Lilly and Company

LLY · New York Stock Exchange

Market cap (USD)$952.3B
Gross margin (TTM)83.8%
Operating margin (TTM)45.6%
Net margin (TTM)31.7%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-01-08
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.

View LLY analysis

Merck & Co., Inc.

MRK · New York Stock Exchange

Market cap (USD)$305.4B
Gross margin (TTM)81.5%
Operating margin (TTM)41.2%
Net margin (TTM)28.1%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2025-12-22
Moat score
71/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Merck & Co., Inc.'s moat claims, evidence, and risks.

View MRK analysis

Comparison highlights

  • Moat score gap: Eli Lilly and Company leads (82 / 100 vs 71 / 100 for Merck & Co., Inc.).
  • Segment focus: Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health); Merck & Co., Inc. has 2 segments (89.5% in Pharmaceutical).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Moderate.
  • Moat breadth: Eli Lilly and Company has 5 moat types across 3 domains; Merck & Co., Inc. has 5 across 3.

Primary market context

Eli Lilly and Company

Cardiometabolic Health

Market

Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)

Geography

Global (with U.S. as the largest market)

Customer

Patients via prescribers and payers (commercial/government)

Role

Branded drug developer/manufacturer

Revenue share

65.5%

Merck & Co., Inc.

Pharmaceutical

Market

Branded prescription pharmaceuticals & human vaccines

Geography

Global

Customer

Wholesalers/retailers, managed care and government payers, hospitals/clinics

Role

R&D-intensive innovator, manufacturer, and marketer

Revenue share

89.5%

Side-by-side metrics

Eli Lilly and Company
Merck & Co., Inc.
Ticker / Exchange
LLY - New York Stock Exchange
MRK - New York Stock Exchange
Market cap (USD)
$952.3B
$305.4B
Gross margin (TTM)
83.8%
81.5%
Operating margin (TTM)
45.6%
41.2%
Net margin (TTM)
31.7%
28.1%
Sector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
HQ country
US
US
Primary segment
Cardiometabolic Health
Pharmaceutical
Market structure
Oligopoly
Competitive
Market share
55%-59% (reported)
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
82 / 100
71 / 100
Moat domains
Legal, Supply, Demand
Legal, Supply, Demand
Last update
2026-01-08
2025-12-22

Moat coverage

Shared moat types

IP Choke PointRegulated Standards PipeCapex Knowhow Scale

Eli Lilly and Company strengths

Capacity MoatReputation Reviews

Merck & Co., Inc. strengths

Scope EconomiesData Workflow Lockin

Segment mix

Eli Lilly and Company segments

Full profile >

Cardiometabolic Health

Oligopoly

65.5%

Oncology

Competitive

19.4%

Immunology

Oligopoly

9.8%

Neuroscience

Competitive

3.3%

Other

Competitive

2%

Merck & Co., Inc. segments

Full profile >

Pharmaceutical

Competitive

89.5%

Animal Health

Oligopoly

9.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.